OBI Pharma announces COVID-19 vaccine clinical trials to start in 2022
02/08/2022 08:38 PM
Taiwan-based biotech firm OBI Pharma Inc. announced Tuesday that the COVID-19 vaccine it developed called BCVax will enter phase 1 & 2 clinical trials in the second half of this year.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Business
U.S. dollar closes sharply higher on Taipei forex market
09/15/2026 04:11 PM - Culture
Tamkang, Sorbonne academics receive Taiwan-France Cultural Award
09/15/2026 04:09 PM - Business
Micron Taiwan union rejects one-time reward package
09/15/2026 03:23 PM - Politics
Taiwan 7th worldwide for citizen input, slips in judicial freedom
09/15/2026 02:59 PM - Society
Wildlife campaigners call for proactive over reactive policymaking
09/15/2026 02:46 PM